	US 11,806,459 B2
	Targeted apheresis to treat preeclampsia
Henry J. Smith, Temecula, CA (US)
Filed by Henry J. Smith, Temecula, CA (US)
Filed on Jan. 16, 2021, as Appl. No. 17/006,875.
Prior Publication US 2022/0233755 A1, Jul. 28, 2022
Int. Cl. A61M 1/36 (2006.01); A61M 1/34 (2006.01); A61K 31/727 (2006.01); A61P 9/12 (2006.01); G01N 33/68 (2006.01); B01D 61/14 (2006.01); B01D 69/02 (2006.01); B01D 15/38 (2006.01)

CPC A61M 1/362 (2014.02) [A61K 31/727 (2013.01); A61M 1/3496 (2013.01); A61P 9/12 (2018.01); B01D 15/3809 (2013.01); B01D 61/145 (2013.01); B01D 69/02 (2013.01); G01N 33/689 (2013.01); A61M 2202/07 (2013.01); G01N 2333/475 (2013.01); G01N 2800/368 (2013.01); G01N 2800/56 (2013.01)]

11 Claims

1. A targeted apheresis method of treating a pregnant woman with preeclampsia, or who is predisposed to develop preeclampsia, wherein the pregnant woman's-blood or plasma is flowed through an apheresis device that contains a) immobilized binding agents that bind and target circulating vascular endothelial growth factor receptors (VEGFRs) selected from sVEGFR-1 and sVEGFR-2; and b) one or more other immobilized binding agents that bind one or more harmful factors selected from the group consisting of: sEndoglin, Endothelin-1, TNF, IL-1, IL-6, IL-12, IL-18, digitalis-like factor, ouabain-like factor, marinobufogenin, marinotoxigenin, and telocinobufagin.